Multiple sclerosis (MS) experts discuss disease causes and current treatment options in a new video series released by the multimedia and peer-reviewed science journal, The American Journal of Managed Care (AJMC).
The free and online video series is part of its “Peer Exchange” initiative, featuring discussions between a panel of opinion leaders representing different therapeutic areas to help guide best practices in disease management.
This series is titled “Identifying Secondary Progressive Multiple Sclerosis,” and features on its panel:
- Peter L. Salgo, MD, a professor of medicine and anesthesiology at Columbia University Vagelos College of Physicians and Surgeons, and an associate director of surgical intensive care at New York-Presbyterian Hospital (moderator).
- Patricia K. Coyle, MD, a professor and interim chair of neurology and director of the Multiple Sclerosis Comprehensive Care Center at Stony Brook University.
- Thomas P. Leist, MD, PhD, director of the Comprehensive Multiple Sclerosis Center at Jefferson University.
- Maria Lopes, MD, MS, former chief medical officer of Magellan Rx Management.
“The panel of experts featured in this educational video series … will outline secondary progressive MS and all treatment options to achieve the best possible outcomes for patients,” Michael J. Hennessy Jr., president of MJH Life Sciences, the parent company of AJMC, said in a press release.
The video series begins with an introductory discussion defining MS and various aspects of disease management.
Leist opens with a talk about recent advances in understanding the pathology of MS. Previously, he says, “we were thinking of multiple sclerosis largely as a white matter disease [affecting conduction and muscle/motor skills]. Now it’s clearly recognized that pathophysiologically, the more important part, is probably also the gray matter pathology [affecting cognition].”
He emphasizes that MS is “a whole brain disease,” and that it “affects essentially the functioning of the individual, and multiple sclerosis is not a T-shirt that says ‘One size fits all.’ There is high variability between individuals.”
Lopes, in turn, discusses the economic burden of living with MS. She notes that direct costs, such as health plan spending on disease-modifying therapies, are relatively easy to calculate. However, as MS patients “lose function, their employability and productivity start to decrease. And so with that comes indirect costs. The impact on family, on dynamics.”
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?